Cue Biopharma (CUE) awards 21,800 restricted stock units to board director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Camardo Daniel A. reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to his continued service with the company. Following this award, he holds 21,800 shares of Common Stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Camardo Daniel A.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 21,800 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 21,800 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
RSUs granted: 21,800 shares
Grant price per share: $0.00
Holdings after transaction: 21,800 shares
+3 more
6 metrics
RSUs granted
21,800 shares
Restricted stock units of Common Stock granted to director Daniel A. Camardo
Grant price per share
$0.00
Recorded transaction price per share for the RSU award
Holdings after transaction
21,800 shares
Total Common Stock directly held by Daniel A. Camardo following the grant
First vesting date
July 9, 2027
One-third of RSUs vest on this date, subject to continued service
Second vesting date
July 9, 2028
One-third of RSUs vest on this date, subject to continued service
Third vesting date
July 9, 2029
Final one-third of RSUs vest on this date, subject to continued service
Key Terms
restricted stock units ("RSUs"), vest, continued service
3 terms
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vest financial
"One-third of the shares subject to the RSUs vest on each of July 9, 2027,"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service financial
"subject to the reporting person's continued service with the issuer through each such vest date."
FAQ
What insider transaction did Cue Biopharma (CUE) report for Daniel A. Camardo?
Cue Biopharma reported that director Daniel A. Camardo received a grant of 21,800 RSUs of Common Stock, recorded at a price of $0.00 per share as equity compensation.
What is the vesting schedule for Daniel A. Camardo’s RSUs at Cue Biopharma (CUE)?
The 21,800 RSUs granted to Daniel A. Camardo vest in three equal installments: one-third on July 9, 2027, one-third on July 9, 2028, and one-third on July 9, 2029, subject to continued service.
Was Daniel A. Camardo’s Cue Biopharma (CUE) RSU grant an open-market purchase?
No. The transaction is coded as a grant (code A) of restricted stock units, recorded at $0.00 per share, indicating equity compensation rather than an open-market purchase or sale.
What are Daniel A. Camardo’s Cue Biopharma (CUE) holdings after this RSU grant?
After the grant, Daniel A. Camardo holds 21,800 shares of Cue Biopharma Common Stock directly, corresponding to the full amount of the 21,800 restricted stock units awarded in this transaction.